Pens for the diabetes drug Ozempic sit on a production line being packaged at Danish drugmaker Novo Nordisk’s plant in Hillerod, Denmark. File | Photo credit: Reuters
Ozempic, an original GLP-1 RA therapy (semaglutide) researched and developed by Novo Nordisk, is now available in India as 0.25 mg, 0.5 mg and 1 mg in FlexTouch Pen.
The weekly price of Ozempic is 0.25mg for ₹2,200, 0.5mg for ₹2,542 and 1mg for ₹2,794.
Ozempic, a once-weekly injectable formulation of semaglutide, is approved in India for adults with type 2 diabetes as first-line treatment, as an adjunct to diet and exercise.
In its release issued on Friday (December 12, 20250), the company said Semaglutide was recently included in the WHO Model List of Essential Medicines – highlighting the proven health benefits of this innovative treatment for people living with diabetes.
According to World Health Organization estimates for 2023–24, India has 101 million (roughly 11.4% of India’s population) people with diabetes, making it the second largest diabetic population in the world after China.
The country also has 136 million individuals with prediabetes and 254 million people living with generalized obesity, signaling an accelerating health problem that requires effective evidence-based therapies.
“Bringing Ozempic to India is a significant milestone,” said Vikrant Shrotriya, Managing Director, Novo Nordisk India.
“Backed by proven clinical excellence and world-class quality, bolstered by a robust supply chain, Ozempic offers Indian physicians a powerful treatment option. Our goal is to provide patients with an innovative and affordable therapy that offers improved glycemic control, meaningful weight management, and long-term heart and kidney protection—all through a simple, easy-to-use pen. This once-a-week treatment demonstrates Novo Nordisk’s commitment to better health outcomes and ongoing health outcomes.”
Published – 12 Dec 2025 19:50 IST
